Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer

J. Jassem, H. Karnicka-Mlodkowska, E. Jassem, A. Słupek, J. Zych, E. Wiatr, S. Malak, R. Moś-Antkowiak, L. Szymaczek-Meyer, A. Pilarska-Machowicz, B. Jereczek

Research output: Contribution to journalArticle

Abstract

From March 1987 to February 1991, 136 patients with untreated small cell lung cancer (64 patients with limited disease and 72 with extensive disease), were treated as part of a prospective multi-center study, with a combination of cyclophosphamide 1000 mg/m2 i.v. on day 1, epirubicin 70 mg/m2 i.v. on day 1 and etoposide 100 mg/m2 i.v. on days 1, 3 and 5. Courses were repeated every 3 weeks. One-hundred thirty-four patients were evaluable. There were 42 (31%) complete responses and 66 (49%) partial responses for an overall response rate of 80% (95% confidence interval 71-87%). A complete response was seen in 24 patients (38%) with limited disease and in 18 patients (26%) with extensive disease, while a partial response was observed for 31 (48%) and in 35 (50%) patients, respectively. The median duration of response for all patients was 8.9 months (range, 1-60+ months). The median duration of survival for the entire group was 11.4 months (12.5 months for limited disease and 9.8 months for extensive disease). The 2-year survival rate for the whole group was 13%. The main side-effects were myelosupression, alopecia, nausea and vomiting. Grade 4 toxicity was seen in 8.5% of patients. In conclusion, the studied regimen was found to be active and well tolerated and may be considered as an alternative to standard chemotherapy combinations in SCLC.

Original languageEnglish
Pages (from-to)283-291
Number of pages9
JournalLung Cancer
Volume11
Issue number3-4
DOIs
Publication statusPublished - 1994

Keywords

  • Chemotherapy
  • Cyclophosphamide
  • Epirubicin
  • Etoposide
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Jassem, J., Karnicka-Mlodkowska, H., Jassem, E., Słupek, A., Zych, J., Wiatr, E., Malak, S., Moś-Antkowiak, R., Szymaczek-Meyer, L., Pilarska-Machowicz, A., & Jereczek, B. (1994). Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer. Lung Cancer, 11(3-4), 283-291. https://doi.org/10.1016/0169-5002(94)90548-7